How do you manage ALK-inhibitor AEs which are low grade but significantly impact patient QOL over time?  

Such as dysgeusia, headache, rash, fatigue, etc



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice
Comments
Medical Oncologist at Yuma Regional Medical Center Cancer Center
Typically, IC50 for the targeted therapy drugs ten...
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution